Applied Cells and Penn Medicine lock research collaboration agreement

In light of the ongoing developments in the field of cancer, Applied Cells, Inc., the USA-based commercial supplier of cell preparation and isolation solutions, has reportedly announced entering into a research collaboration with the Perelman School of Medicine at University of Pennsylvania.

Speculations have it that the agreement would allow the organizations to undertake research on rare cell isolation of breast cancer dispersed tumor cells in bone marrow.

As per official reports, Applied Cells MARS Technologies would be used in a multi-center trial as a part of the company’s 2- PREVENT Translational Center of Excellence to analyze their character in the diagnosis of breast cancer residual disorder.

News reports suggest that Penn’s 2-PREVENT program highlights the collaboration of clinical and basic science research with the motive of enhancing the prevention, surveillance, and treatment of recurrent breast cancer.

In fact, Applied Cells MARS technologies would be analyzed in clinical trials to determine whether they will potentially enrich low frequency cancer cells in the samples of bone marrow to help generate increased rate of recovery.

Moreover, Applied Cells MARS workflow has also been deemed to reduce human factors and ensure standardized operation, that are required for the research trial.

Speaking on the accomplishment, CEO of Applied Cells, Dr. Yuchen Zhou stated that the firm is delighted that its MARS technologies have an opportunity to be tested for the ability to offer simplicity and desired performance.

Dr. Zhou added that the team of Applied Cells is excited to have further partnered with Penn Medicine to make use of MARS to investigate the success rate of diagnosing rare cancer cells in multi-center breast cancer trial.  

On the other hand, Chairman of the Dept. of Cancer Biology in the Perelman School of Medicine at the University of Pennsylvania, Dr. Lewis Chodosh stated that the institution believes that this novel approach bears the ability to enhance the sensitivity with which the critical pool of cancer cells can be detected and analyzed in patients.

Source Credit: